释放希望:乌斯特基努马布生物类似药在克罗恩氏病治疗中的未来
Ferdinando D'Amico1, Sarah Bencardino1, André Gonçalves2
1Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
United European gastroenterology journal
|February 19, 2025
概括
乌斯特基努马布生物仿制药在克罗恩病中提供了可比的疗效和安全性.
科学领域:
- 胃肠道学和免疫学
- 药理学和治疗学 药理学和治疗学
背景情况:
- 生物疗法,包括ustekinumab,已经改变了克罗恩氏病 (CD) 治疗.
- 生物制剂的高成本限制了患者的获取.
- 乌斯特基努马布向介质蛋白12-23并用于中度至重度的CD.
研究的目的:
- 审查对中度至重度克罗恩病的乌斯特基努马布生物类似药的现有数据.
- 评估在CD管理中使用ustekinumab生物仿制药的优缺点.
- 讨论生物类似药对CD治疗算法的潜在影响.
主要方法:
- 审查现有的科学文献和关于乌斯特基努马布生物类似药的临床数据.
- 对疗效,药理动力学,安全性和免疫性数据的分析.
- 评估成本节约潜力和对治疗可访问性的影响.
主要成果:
- 乌斯特基努马布生物仿制药的疗效,药理动力学,安全性和免疫性与参考产品具有可比性.
- 生物类药物已被批准用于CD基于外推,目前现实世界数据有限.
- 预计通过引入乌斯特基努马布生物仿制药,将大大节省成本.
结论:
- 乌斯特基努马布生物仿制药有望增加对中度至重度CD的有效治疗的获取.
- 需要进一步的现实数据才能充分了解它们对CD治疗领域的长期影响.
- 生物类药物为克罗恩病的经济有效管理提供了一个有希望的途径.
关键词:
在ABP 654中使用.AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04 AVT04BFI-751 一个问题.在 CT-P43 中.克罗恩氏病是什么 克罗恩氏病是什么IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD美国SB17法案炎症性肠道疾病 炎症性肠道疾病发起人 发起人 发起人治疗疗法治疗疗法治疗疗法相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
110
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
110
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
135
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
135
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Inflammatory Bowel Disease IV: Pharmacological Management
95
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
95
Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
Inflammatory Bowel Disease II: Crohn's Disease
166
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
166


